Dyslipidemia in type 2 diabetes mellitus – a major risk factor for cardiovascular morbidity
Abstract
Introduction: Diabetes mellitus is growing worldwide like an epidemic. Early identification of cardiovascular risk factors will decrease the morbidity in type 2 diabetes mellitus. This study was done to assess the prevalence of dyslipidemia among type 2 diabetic population.
Methods: 40 cases of type 2 DM with duration of 8 to 12 yrs and 40 controls of both males and females in the age group of 40 to 65yrs were selected. Laboratory investigations like fasting glucose and lipid profile (fasting) were taken.
Results: In the present study the levels of fasting glucose, total cholesterol, low density lipoproteins, triglycerides were high and the levels of high density lipoproteins were low in the type 2 diabetics compared to controls.
Conclusion: Thus this study suggests the importance of early detection of dyslipidemia in type 2 diabetics mellitus and will reduce the prevalence of complications in diabetics.
Downloads
References
2. Tranche S, Galgo A, Mundet X, Sánchez-Zamorano MA; Karen AP Study Investigators. Cardiovascular risk factors in type 2 diabetic patients: multifactorial intervention in primary care. Kidney Int Suppl. 2005 Jan;(93):S55-62. [PubMed]
3. Ahmed S, Cannon C P,Murphy SA, and Braunwald E. Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT -TIMI 22 trial. European Heart journal.2006; 27: 2323-2329. doi:10.1093/eurheartj/ehl220.
4. Chen G, McAlister FA, Walker RL, Hemmelgarn BR, Campbell NR. Cardiovascular outcomes in framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011 May;57(5):891-7. doi: 10.1161/HYPERTENSIONAHA.110.162446. Epub 2011 Mar 14.
5. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004 Jan 21;291(3):335-42.
6. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001 Nov;24(11):1957-60. [PubMed]
7. Haffner SM, SeppoLehto, Ronnemmaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. New England J Med. 1998; Jul 339(4): 229-234.
8. Fox CS, Coady S, Sorlie PD, Levy D, Meigs JB, D'Agostino RB Sr, Wilson PW, Savage PJ. Trends in cardiovascular complications of diabetes. JAMA. 2004 Nov 24;292(20):2495-9. [PubMed]
9. Taylor HA Jr, Akylbekova EL, Garrison RJ, Sarpong D, Joe J, Walker E, Wyatt SB, Steffes MW. Dyslipidemia and the treatment of lipid disorders in African Americans. Am J Med. 2009 May;122(5):454-63. doi: 10.1016/j.amjmed.2008.09.049. [PubMed]
10. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003 Oct;26(10):2713-21.
11. Selvin E, Coresh J, Golden SH, Boland LL, Brancati FL, Steffes MW; Atherosclerosis risk in communities study. Glycemic control, atherosclerosis, and risk factors for cardiovascular disease in individuals with diabetes: the atherosclerosis risk in communities study. Diabetes Care. 2005 Aug;28(8):1965-73.
12. Gavin JR 3rd. Reducing global cardiovascular risk in patients with type 2 diabetes mellitus. J Am Osteopath Assoc. 2008 May;108(5 Suppl 3):S14-9. [PubMed]
13. Rani HS, Madhavi G, Rao VR, Sahay BK, Jyothy A. Risk factors for coronary heart disease in type II diabetes mellitus. Indian J Clin Biochem. 2005 Jul;20(2):75-80. doi: 10.1007/BF02867404.
OAI - Open Archives Initiative
